| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2019-02-14 | Passage Bio (USA - PA) | $115.5 million | series A financing round | OrbiMed Advisors (USA - NY) Frazier Healthcare Partners (USA - WA) Versant Ventures (USA - CA) New Leaf Venture Partners (USA - NY - CA) Vivo Capital (USA - CA) Lilly Asia Ventures (China) | Rare diseases - Genetic diseases - CNS diseases | Series A financing round |
| 2019-01-25 | Nordic Nanovector (Norway) | NOK 222 million ($ 26 million) | private placement | Cancer - Oncology | Private placement | |
| 2019-01-25 | Corbus Pharmaceuticals (USA - MA) | private placement | Inflammatory diseases | Private placement | ||
| 2019-01-24 | Wave Life Sciences (USA - MA) | $150 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2019-01-24 | Wave Life Sciences (USA - MA) | $150 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2019-01-23 | Orion (Finland) | € 100 million | loan | European Investment Bank (EIB) | Cancer - Oncology - Neurological diseases - Respiratory diseases | Loan |
| 2019-01-23 | PTC Therapeutics (USA - NJ) | private placement | Rare diseases - Genetic diseases | Private placement | ||
| 2019-01-23 | Selecta Biosciences (USA - MA) | $30 million | private placement | Private placement | ||
| 2019-01-22 | Alvotech (Iceland) | $300 million | private placement | Autoimmune diseases - Inflammatory diseases - Cancer - Oncology | Private placement | |
| 2019-01-04 | Aimmune Therapeutics (USA - CA) | $ 170 million | loan | KKR (USA - NY) | Allergic diseases | Loan |
| 2019-01-03 | Cabaletta Bio (USA - PA) | $50 million | series B financing round | Adage Capital (USA - MA) 5AM Ventures (USA - MA) Deerfield Management Company (USA - NY) Boxer Capital of Tavistock Group (Bahamas) Redmile Group (USA - CA) Cormorant Capital (USA - IL) | Autoimmune diseases | Series B financing round |
| 2018-12-21 | Nabriva Therapeutics (Ireland) | $75 million | loan | Hercules Capital (USA - CA) | Infectious diseases | Loan |
| 2018-12-20 | Geneuro (Switzerland) | €7.5 million | credit line | GNEH (France) | Neurodegenerative diseases | Loan |
| 2018-12-14 | Axovant Sciences (Bermuda - USA - NY) | $ 30 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-11-26 | Adrenomed (Germany) | € 24 million | series D financing round | HBM Healthcare Investments (Switzerland) Wellington Partners (Germany - UK) | Inflammatory diseases | Series D financing round |
| 2018-11-02 | Omeicos Therapeutics (Germany) | € 17 million | series C financing round | Forbion Capital Partners (The Netherlands) Vesalius Biocapital (Luxembourg) SICAR (Luxembourg) VC Fonds Technologie Berlin (Germany) Hightech Gruenderfonds II GmbH & Co. KG (HTGF) (Germany) KfW Group (Germany) The Falck Revocable Trust, members of the management | Cardiovascular diseases - Ophtalmological diseases | Series C financing round |
| 2018-10-30 | Orchard Therapeutics (UK) | IPO | Rare diseases - Genetic diseases | IPO | ||
| 2018-10-30 | Newron Pharmaceuticals (Italy) | € 40 million | loan | European Investment Bank (EIB) | CNS diseases - Neurological diseases | Loan |
| 2018-10-25 | 89Bio (USA - CA) | $60 million | series A financing round | OrbiMed (USA - NY) Longitude Capital (USA - CA) RA Capital Management (USA - MA) Pontifax (Israel) | Hepatic diseases - Liver diseases | Series A financing round |
| 2018-10-23 | Cerevel Therapeutics (USA - MA) | $350 million | financing round | Pfizer (USA - NY) Bain Capital (USA - MA) | CNS diseases | Financing round |
